Business
Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update
Second quarter 2021 total revenue of $87.0 million including Crysvita1 revenue to Ultragenyx of $44.7 million 2021 Crysvita revenue in Ultragenyx territories1
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"Second quarter 2021 total revenue of $87.0 million including Crysvita1 revenue to Ultragenyx of $44.7 million 2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch continues with approximately 220 patients on reimbursed commercial therapy in the United States Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome to begin enrolling patients in Canada and the U.K.; U.S. pending protocol revisions NOVATO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the second quarter 2021 and reaffirmed its financial guidance for 2021. “In the first half of 2021 we have advanced all our commercial, clinical, and regulatory priorities. This has led to meaningful revenue growth in the second quarter and has positioned us well as we enter a period of significant execution on our clinical programs in the second half of this year,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “We have one of the most robust late-stage pipelines in both gene therapy and other biologics for rare diseases and are on track to initiate four pivotal clinical trials over the next six months.” Second Quarter 2021 Financials In the second quarter 2021, Crysvita revenue in Ultragenyx territories1 increased 38% versus the second quarter 2020. This increase is driven by demand from pediatric and adult patients with X-linked hypophosphatemia (XLH) and patients with tumor induced osteomalacia (TIO), which became Crysvita’s second approved indication in the United States in June 2020. Dojolvi revenue in the second quarter 2021 continued to build on the launch momentum after the U.S. Food and Drug Administration (FDA) approval in June 2020. As of the end of the second quarter 2021, the company has received approximately 270 completed start forms from approximately 130 unique prescribers. This has led to approximately 220 patients on reimbursed therapy as of the end of June 2021. Second quarter 2021 revenue included $22.0 million related to the technology transfer as part of the Daiichi Sankyo strategic manufacturing partnership around th...